J 2024

ERS statement on transition of care in childhood interstitial lung diseases

POHUNEK, Petr, Effrosyni MANALI, Susanne VIJVERBERG, Julia CARLENS, Felix CHUA et. al.

Basic information

Original name

ERS statement on transition of care in childhood interstitial lung diseases

Authors

POHUNEK, Petr, Effrosyni MANALI, Susanne VIJVERBERG, Julia CARLENS, Felix CHUA, Ralph EPAUD, Carlee GILBERT, Matthias GRIESE, Bulent KARADAG, Eitan KEREM, Václav KOUCKÝ, Nadia NATHAN, Spyridon PAPIRIS, Suzanne TERHEGGEN-LAGRO, Lukáš PLCH, Alba Torrent VERNETTA and Andrew BUSH

Edition

EUROPEAN RESPIRATORY JOURNAL, ENGLAND, EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2024, 0903-1936

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 24.300 in 2022

DOI

Tags

International impact, Reviewed
Změněno: 21/6/2024 14:07, Mgr. Lukáš Plch

Abstract

V originále

Interstitial lung diseases (ILD) are a heterogeneous group of rare diffuse diseases affecting the lung parenchyma in children and adults. Childhood interstitial lung diseases (chILD) are often diagnosed at very young age, affect the developing lung, and can have different presentations and prognosis compared to adult forms of these diseases. Also, chILD in many cases may apparently remit, and have a better response to therapy and better prognosis than adult ILD. Many affected children will reach adulthood with minimal activity or clinical remission of the disease. They need continuing care and follow-up from childhood to adulthood if the disease persists and progresses over time but also if they are asymptomatic and in full remission. Therefore, for every chILD patient an active transition process from paediatric to adult care should be guaranteed. This ERS statement provides a review of the literature and current practice concerning transition of care in chILD. It draws on work in existing transition care programs in other chronic respiratory diseases, disease-overarching transition of care programs, evidence on the impact of these programs on clinical outcomes, current evidence regarding long-term remission of chILD as well as the lack of harmonisation between the current adult ILD and chILD classifications impacting on transition of care. While the transition system is well established in several chronic diseases, such as cystic fibrosis or diabetes mellitus, we could not find sufficient published evidence on transition systems in chILD. This statement summarises current knowledge but cannot yet provide evidence-based recommendations for clinical practice.